Nrose Doctor brochure - Flipbook - Page 21
Fillers
Rethinking the HA Filler Market
Intense Rose is based on a unique patented Smart Crosslinking Technology
which is an
innovative and advanced technology that combines Hyaluronic Acid and PEGDE in one network.
Intense Rose is enriched with Glycine and L-Proline.
PIONEER with PEG
PEG is a well-known polymer in the pharmaceutical market, due to its uniqueness, versatility and safety profile.1,2
Neauvia chose PEG, as a crosslinker, differentiating itself in the market and presenting the following main features:
HIGH-SAFETY PROFILE:
1 No pathologic inflammatory reactions*3
2 No citotoxicity activity detected4
3 No crosslinker residuals remain and no changes
in the surrounding tissues can be observed
after complete degradation3
4 Reversible filling3,5
DISTINCTIVE CHARACTERISTICS:
1 Mechanical properties that mimic those
of natural skin tissues1,6
2 High cohesivity and balanced viscoelasticity3,7
3 High resistance to heat and high thermodynamic
stability6 to allow combined protocols
4 Temporary filling decreasing at 6 months3
GLYCINE and L-PROLINE
Neauvia‘s fillers are enriched with Glycine and L-Proline, which are proteinogenic amino acids used in the
biosynthesis of proteins3. They are added to the phosphate buffer solution to tune the rheological properties
(viscoelastic properties) and the swelling resistance3. They ensure in Neauvia’s fillers formulation a better control
of the hydrogel swelling capacity in the postimplant phase.8
* None detected so far with the use of Neauvia PEG-HA Devices.
1. Marino F, Cosentino M, Legnaro M, Luini A, Sigova J, Mocchi R, Lotti T and Zerbinati N. Immune profile of Hyaluronic Acid hydrogel Polyethylene Glycol crosslinked: an in vitro evaluation in human polymorphonuclear leukocytes.
Dermatologic Therapy. 2020; e13388. https://doi.org/10.1111/dth.1338
2. Jeong CH, Kim DH, Yune JH, Kwon HC, Shin DM, Sohn H, Lee KH, Choi B, Kim ES, Kang JH, Kim EK and Han SG. In vitro toxicity assessment of crosslinking agents used in Hyaluronic Acid dermal filler. Toxicology in Vitro, Volume 70,
2021, 105034, ISSN 0887-2333. https://doi.org/10.1016/j.tiv.2020.105034
3. Clinical data on file.
4. Zerbinati N, Lotti T, Monticelli D, Rauso R, González-Isaza P, D’Este E, Calligaro A, Sommatis S, Maccario C, Mocchi R, Lotti J, Wollina U, Tchernev G and França K. In vitro evaluation of the biosafety of Hyaluronic Acid PEG cross-linked
with micromolecules of Calcium Hydroxyapatite in low concentration. Open Access Maced J Med Sci. https://doi.org/10.3889/oamjms.2018.044
5. Zerbinati N, Lotti T, Monticelli D, Martina V, Cipolla G, D’Este E, Calligaro A, Mocchi R, Maccario C, Sommatis S, Lotti J, Wollina U, Tchernev G and França K. In vitro evaluation of the sensitivity of a Hyaluronic Acid PEG cross-linked
to bovine testes Hyaluronidase. Open Access Maced J Med Sci. https://doi.org/10.3889/oamjms.2018.046
6. Zerbinati N, Capillo MC, Sommatis S, Maccario C, Alonci G, Rauso R, Galadari H, Guida S and Mocchi R. Rheological investigation as tool to assess physicochemical stability of a Hyaluronic Acid dermal filler cross-linked with
Polyethylene Glycol Diglycidyl Ether and containing Calcium Hydroxyapatite, Glycine and L-Proline. Gels 2022, 8, 264. https://doi.org/10.3390/gels8050264
7. Zerbinati N, Sommatis S, Maccario C, Capillo MC, Grimaldi G, Alonci G, Protasoni M, Rauso R and Mocchi R. Toward physicochemical and rheological characterization of different HA dermal fillers cross-linked with Polyethylene
Glycol Diglycidyl Ether. Polymers 2021, 13, 948. https://doi.org/10.3390/polym13060948
8. Martina V, Gallo A, Tarantino E, Esposito C, Zerbinati U, Mocchi R, Monticelli D, Lotti T, Tirant M, Van Thuong N, Rauso R and Zerbinati N. Viscoelastic properties and thermodynamic balance improvement of a Hyaluronic Acid
hydrogel enriched with Proline and Glycyne. Journal of Biological Regulators and Homeostatic Agents. 2019 Nov-Dec;33(6):1955-1959. https://doi.org/10.23812/19-252-L.
